Data updated: Mar 10, 2026
JESDUVROQ
DAPRODUSTAT
Approved 2023-02-01
1
Indication
--
Phase 3 Trials
3
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2023-02-01
- Routes
- ORAL
- Dosage Forms
- TABLET
JESDUVROQ Approval History
Loading approval history...
What JESDUVROQ Treats
1 FDA approvalsOriginally approved for its first indication in 2023 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
JESDUVROQ FDA Label Details
ProJESDUVROQ Patents & Exclusivity
Latest Patent: Mar 2038
Exclusivity: Jan 2028
Patents (150 active)
US11117871
Expires Mar 13, 2038
US11649217
Expires Mar 13, 2038
US8324208
Expires Dec 11, 2028
US8815884
Expires Jun 22, 2027
US8557834
Expires Jun 22, 2027
US11643397
Expires Jun 22, 2027
+ 140 more patents
Exclusivity
NCE
Until Feb 2028
NCE
Until Feb 2028
NCE
Until Feb 2028
NCE
Until Feb 2028
NCE
Until Feb 2028
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.